EPISODE · May 1, 2026 · 18 MIN
Theranos 2018 : Governance Theater & Board Composition vs. Board Function | GP/LP Analysis - 3 Red Flags | EP21 T2
from Financial Forensics: Autopsy Files · host Sergio Stieben
Theranos had a board that included George Shultz, James Mattis, and Henry Kissinger. It had no one with clinical laboratory science expertise, no one with medical device regulatory experience, and no scientific advisory committee with access to real performance data. The board was not designed to govern the technology. It was designed to signal legitimacy to investors who would not look past the names. This episode dissects the governance architecture that made the fraud possible — the three structural conditions that convert a board from an oversight mechanism into a validation tool, and the three due diligence questions that would have ended the Theranos valuation in any year they were asked. For GPs and LPs evaluating early-stage deep tech with proprietary technology claims.🔴 Every corporate failure leaves behind a pattern. FFL Risk Pattern Scan provides access to a searchable library of documented corporate collapses, frauds and restructurings that can be filtered by geography, sector, collapse mechanism and fraud vector. Compare live opportunities against historical cases using pattern matching and risk assessment tools designed for investors, lenders and deal teams. All analysis runs locally and remains private.https://risk-pattern-scan.lovable.app/ The board had no members with clinical laboratory or medical device expertise. The technology had never been independently validated by a peer-reviewed process. The NDA structure prevented investors from speaking to scientists who had worked on the device. Three signals. Available before the Wall Street Journal investigation. Not acted on because the narrative was more compelling than the verification. This episode dissects the Theranos governance theater mechanism, the board composition versus board function gap, and the three institutional due diligence signals that indicated a technology claim with no independent scientific validation behind a $9 billion valuation. GP/LP analysis. Healthcare due diligence. Board governance. Technical validation risk. Startup fraud detection. Financial Forensics Labs — GP/LP Analysis. Every collapse has a pattern. We dissect it. Layer by layer.
What this episode covers
Theranos had a board that included George Shultz, James Mattis, and Henry Kissinger. It had no one with clinical laboratory science expertise, no one with medical device regulatory experience, and no scientific advisory committee with access to real performance data. The board was not designed to govern the technology. It was designed to signal legitimacy to investors who would not look past the names. This episode dissects the governance architecture that made the fraud possible — the three structural conditions that convert a board from an oversight mechanism into a validation tool, and the three due diligence questions that would have ended the Theranos valuation in any year they were asked. For GPs and LPs evaluating early-stage deep tech with proprietary technology claims.🔴 Every corporate failure leaves behind a pattern. FFL Risk Pattern Scan provides access to a searchable library of documented corporate collapses, frauds and restructurings that can be filtered by geography, sector, collapse mechanism and fraud vector. Compare live opportunities against historical cases using pattern matching and risk assessment tools designed for investors, lenders and deal teams. All analysis runs locally and remains private.https://risk-pattern-scan.lovable.app/ The board had no members with clinical laboratory or medical device expertise. The technology had never been independently validated by a peer-reviewed process. The NDA structure prevented investors from speaking to scientists who had worked on the device. Three signals. Available before the Wall Street Journal investigation. Not acted on because the narrative was more compelling than the verification. This episode dissects the Theranos governance theater mechanism, the board composition versus board function gap, and the three institutional due diligence signals that indicated a technology claim with no independent scientific validation behind a $9 billion valuation. GP/LP analysis. Healthcare due diligence. Board governance. Technical validation risk. Startup fraud detection. Financial Forensics Labs — GP/LP Analysis. Every collapse has a pattern. We dissect it. Layer by layer.
NOW PLAYING
Theranos 2018 : Governance Theater & Board Composition vs. Board Function | GP/LP Analysis - 3 Red Flags | EP21 T2
No transcript for this episode yet
Similar Episodes
Apr 6, 2026 ·25m
Mar 30, 2026 ·27m